Everolimus

CHEMBL1908360 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

958.2 g/mol

LogP

5.9

Phase

4

This medication works by blocking a key signaling pathway called mTOR that many cancer cells rely on to grow, and also suppresses the immune system to prevent organ rejection after transplant. It is used for both cancer treatment and transplant medicine.

Masse moléculaire

958,2000 g/mol

LogP

5,90

TPSA

205,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Age-Related Macular Degeneration Pain Management Non-Small Cell Lung Cancer Epilepsy Melanoma Oncology Systemic Lupus Erythematosus Chronic Kidney Disease Lymphoma Type 2 Diabetes Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C

InChI

InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

Molecular Formula

C53H83NO14

HBD / HBA

3 / 14

Liaisons Rotatives

9

Atomes Lourds

68

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This medication works by blocking a key signaling pathway called mTOR that many cancer cells rely on to grow, and also suppresses the immune system to prevent organ rejection after transplant. It is used for both cancer treatment and transplant medicine.

Yes, Everolimus is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1908360. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6442177. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Everolimus sur PillFYI

Structure

Données Clés

Formule: C53H83NO14
Synonymes: 3

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.